GoldenGolden
Advanced Search
Akcea Therapeutics

Akcea Therapeutics

Akcea Therapeutics is a Cambridge, Massachusetts-based therapeutics and pharmaceuticals company.

Akcea Therapeutics is a wholly owned subsidiary of Ionis Pharmaceuticals, a leader in RNA therapeutics. Akcea commercializes two medicines, and with Ionis, is advancing a mature pipeline of novel medicines discovered by Ionis and based on Ionis’ proprietary antisense technology.

Akcea's priority is to bring transformative medicines to patients by understanding patient and physician needs, preparing the market, creating market access, and commercializing its products on a global basis.

Akcea Therapeutics has been acquired by Ionis Pharmaceuticals.

Timeline

Patents

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
June 29, 2021
BioSpace
Catalyst Pharmaceuticals, Inc. today announced the appointment of Molly Harper to the Company's Board of Directors.
BioSpace
June 9, 2021
BioSpace
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021.
BioSpace
May 25, 2021
BioSpace
Expansion of management team continues with addition of an industry leader with deep experience in business development, licensing, and strategy in the life-science industry
Ionis Pharmaceuticals, Inc.
February 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the fourth quarter of 2020 and recent business highlights....
Ionis Pharmaceuticals, Inc.
December 9, 2020
www.prnewswire.com:443
/PRNewswire/ -- At its Investor Day yesterday, Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) highlighted the company's significant achievements in 2020 and...
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.